Certain crystalline diphenylazetidinone hydrates,...

Details Certain crystalline diphenylazetidinone hydrates,... Certain crystalline diphenylazetidinone hydrates,...

2011-08-23

2011-08-23

Berch, Mark (Department: 1622)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C540S200000

Reexamination Certificate

active

08003636

ABSTRACT:
Provided are certain crystalline hydrates of the formula Iin which n has a value of from 0.5 to 1.8. The compound may be suitable, for example, as a hypolipidemic.

REFERENCES:
patent: 4596789 (1986-06-01), Dutta et al.
patent: 5190923 (1993-03-01), Vincent et al.
patent: 5656624 (1997-08-01), Vaccaro et al.
patent: 5756470 (1998-05-01), Yumibe et al.
patent: 5846966 (1998-12-01), Rosenblum et al.
patent: 5889002 (1999-03-01), Nielsen et al.
patent: 6221633 (2001-04-01), Ertl et al.
patent: 6221897 (2001-04-01), Frick et al.
patent: 6225310 (2001-05-01), Nielsen et al.
patent: 6245744 (2001-06-01), Frick et al.
patent: 6268343 (2001-07-01), Knudsen et al.
patent: 6342512 (2002-01-01), Kirsch et al.
patent: 6380230 (2002-04-01), Brodin et al.
patent: 6498156 (2002-12-01), Glombik et al.
patent: 6525083 (2003-02-01), Acton, III et al.
patent: 6589984 (2003-07-01), Naniwa et al.
patent: 6624185 (2003-09-01), Glombik et al.
patent: 6861444 (2005-03-01), Ikuta et al.
patent: 6884812 (2005-04-01), Glombik et al.
patent: 6992067 (2006-01-01), Glombik et al.
patent: 7067689 (2006-06-01), Renze et al.
patent: 7205290 (2007-04-01), Jaehne et al.
patent: 7388004 (2008-06-01), Jaehne et al.
patent: 7390790 (2008-06-01), Jaehne et al.
patent: 7407938 (2008-08-01), Jaehne et al.
patent: 7488829 (2009-02-01), Glombik et al.
patent: 7579339 (2009-08-01), Jaehne et al.
patent: 7671047 (2010-03-01), Jaehne et al.
patent: 2003/0212070 (2003-11-01), Schwink et al.
patent: 2004/0077623 (2004-04-01), Jaehne et al.
patent: 2004/0082561 (2004-04-01), Jaehne et al.
patent: 2005/0239766 (2005-10-01), Starke et al.
patent: 2005/0267038 (2005-12-01), Glombik et al.
patent: 2007/0149501 (2007-06-01), Jendralla et al.
patent: 2007/0197498 (2007-08-01), Jaehne et al.
patent: 2008/0274947 (2008-11-01), Jaehne et al.
patent: 2008/0281092 (2008-11-01), Glombik et al.
patent: 2008/0319218 (2008-12-01), Haubrich et al.
patent: 2008/0319221 (2008-12-01), Junker et al.
patent: 2010/0160282 (2010-06-01), Glombik et al.
patent: 2 136 893 (2002-06-01), None
patent: 0 462 884 (1991-12-01), None
patent: 0 656 354 (1995-06-01), None
patent: WO 97/16455 (1997-05-01), None
patent: WO 97/26265 (1997-07-01), None
patent: WO 97/41097 (1997-11-01), None
patent: WO 97/45406 (1997-12-01), None
patent: WO 98/08871 (1998-03-01), None
patent: WO 99/03861 (1999-01-01), None
patent: WO 99/15525 (1999-04-01), None
patent: WO 99/46262 (1999-09-01), None
patent: WO 00/34331 (2000-06-01), None
patent: WO 00/40569 (2000-07-01), None
patent: WO 00/63703 (2000-10-01), None
patent: WO 00/64876 (2000-11-01), None
patent: WO 00/64888 (2000-11-01), None
patent: WO 00/71549 (2000-11-01), None
patent: WO 00/78312 (2000-12-01), None
patent: WO 01/04156 (2001-01-01), None
patent: WO 01/09111 (2001-02-01), None
patent: WO 01/62266 (2001-08-01), None
patent: WO 01/83451 (2001-11-01), None
patent: WO 01/85695 (2001-11-01), None
patent: WO 01/90094 (2001-11-01), None
patent: WO 02/44150 (2002-06-01), None
patent: WO 02/50027 (2002-06-01), None
patent: WO 03/015769 (2003-02-01), None
patent: WO 2009112203 (2009-09-01), None
Copending U.S. Appl. No. 11/155,109, filed Jun. 17, 2005, Glombik et al.
Copending U.S. Appl. No. 11/767,284, filed Jun. 22, 2007, Haubrich et al.
Copending U.S. Appl. No. 12/219,196, filed Jul. 17, 2008, Glombik et al.
Copending U.S. Appl. No. 12/271,236, filed Nov. 13, 2008, Junker et al.
Castañer, R. M., et al., “Ezetimbe, Hypolipidemic Cholesterol Absorption Inhibitor SCH-58235,”Drugs of the Future2000, 25(7):679-685.
Goodman and Gilman'sThe Pharmacological Basis of Therapeutics, 10th Ed., 2001, p. 54.
Kosoglou, T., et al., “Coadministration of Simvastatin and Ezetimibe Leads to Significant Reduction in LDL-Cholesterol,”Proceedings of the 3rd International Congress on Coronary Artery Disease: From Prevention to Intervention, 2000, p. 275.
Vaccaro, W. D., et al., “Sugar-Substituted 2-Azetidinone As Cholesterol Absorption Inhibitors,”Biorganic&Medicinal Chemistry Letters8(1998):35-40.
Vaccaro, W. D., et al., “Sugar-Substituted 2-Azetidinone Cholesterol Absorption Inhibitors: Enhanced Potency by Modification of the Sugar,”Biorganic&Medicinal Chemistry Letters8(1998):313-318.
van Heek, M., et al., “Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663,”British Journal of Pharmacology129:1748-1754 (2000).
Zaks, A., et al., “Enzymatic Glucuronidation of a Novel Cholesterol Absorption Inhibitor, SCH58235,”Applied Biochemistry and Biotechnology, 73:205-214 (1998).
Non-Final Office Action for U.S. Appl. No. 10/021,502 (issued patent 6,992,067), mailed on Sep. 10, 2003, 4 pages.
Final Office Action for U.S. Appl. No. 10/021,502 (issued patent 6,992,067), mailed on Apr. 16, 2004, 11 pages.
Non-Final Office Action for U.S. Appl. No. 10/021,502 (issued patent 6,992,067), mailed on Aug. 25, 2004, 5 pages.
Non-Final Office Action for U.S. Appl. No. 10/021,502 (issued patent 6,992,067), mailed on Feb. 8, 2005, 9 pages.
Notice of Allowance for U.S. Appl. No. 10/021,502 (issued patent 6,992,067), mailed on Jul. 12, 2005, 4 pages.
Office Action for U.S. Appl. No. 10/813,954 (issued patent 7,205,290), mailed on May 18, 2006, 8 pages.
Notice of Allowance for U.S. Appl. No. 10/813,954 (issued patent 7,205,290), mailed on Nov. 27, 2006, 4 pages.
Office Action for U.S. Appl. No. 11/155,109 mailed on Aug. 17, 2006, 9 pages.
Final Office Action for U.S. Appl. No. 11/155,109 mailed on Feb. 14, 2007, 7 pages.
Office Action for U.S. Appl. No. 11/155,109 mailed on Jul. 16, 2007, 10 pages.
Final Office Action for U.S. Appl. No. 11/155,109 mailed on Jan. 9, 2008, 7 pages.
Notice of Panel Decision from Pre-Appeal Brief Review U.S. Appl. No. 11/155,109 mailed on May 2, 2008, 3 pages.
Examiner's Answer to Appeal Brief for U.S. Appl. No. 11/155,109 mailed on Aug. 6, 2008, 9 pages.
Office Action for U.S. Appl. No. 11/155,109 mailed on Dec. 3, 2008, 9 pages.
Notice of Allowance for U.S. Appl. No. 11/177,410 (issued patent 7,067,689), mailed on Mar. 31, 2006, 4 pages.
Office Action for U.S. Appl. No. 11/767,298, mailed Aug. 15, 2008, 5 pages.
Office Action for U.S. Appl. No. 11/797,720 (issued patent 7,488,829), mailed on Nov. 16, 2007, 6 pages.
Final Office Action for U.S. Appl. No. 11/797,720 (issued patent 7,488,829), mailed on Apr. 21, 2008, 8 pages.
Notice of Allowance for U.S. Appl. No. 11/797,720 (issued patent 7,488,829), mailed on Oct. 2, 2008, 6 pages.
Asakawa, A. et al., Cocaine-Amphetamine-Regulated Transcript Influences Energy Metabolism, Anxiety and Gastric Emptying in Mice, Hormone and Metabolic Research, 2001, vol. 33, No. 9, pp. 554-558.
Barf, T. et al., Arylsulfonamidothiazoles as a New Class of Potential Antidiabetic Drugs, Discovery of Potent and Selective Inhibitors of the 11 β-Hydroxysteroid Dehydrogenase Type 1, Journal of Medicinal Chemistry, 2002, vol. 45, No. 18, pp. 3813-3815.
Chaudhary, A. et al., CO2Offgas as a Mechanistic Probe and Scale-Up Tool in N-Acylations Using Mixed Anhydrides from Amino Acids and Isobutyl Chloroformate, Organic Process Research and Development, 2003, vol. 7, pp. 888-895.
Greene, T. et al., Protective Groups in Organic Synthesis, John Wiley and Sons, Inc., 1999, 3rdEd., pp. 1, 4-5, 372-374, 383-387, 415-419, 701-702, 705-707, and 728-731.
Ishihara, K. et al., 3,4,5-Trifluorobenzeneboronic Acid as an Extremely Active Amidation Catalyst, Journal of Organic Chemistry, 1996, vol. 61, pp. 4196-4197.
Klausner, Y. et al., Coupling Reagents'in Peptide Synthesis, Synthesis, 1972, No. 9, pp. 453-463.
Kunishima, M. et al., 4-(4,6-Dimethoxy-1,3,5-triazin-2-yl)-4-methyl-morpholiniurn Chloride: An Efficient Condensing Agent Leading to the Formation of Amides and Esters, Tetrahedron, 1999, vol. 55, pp. 13159-13170.
Larock, R., Interconversion of Nitriles, Carboxylic Acids and Derivatives, Comprehensive Organic Transformations: A Guide to Functional Group Preparations, VCH Publishers, New York, 1999, 2ndEd., pp. 1929-1930.
Lee, D. et al., Leptin Agonis

Affiliated with

Also associated with

Rating

Certain crystalline diphenylazetidinone hydrates,... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Certain crystalline diphenylazetidinone hydrates,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Certain crystalline diphenylazetidinone hydrates,... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2621882